相关实验视频
Updated: Jan 8, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
875
药物治疗用于肥胖管理的药物治疗
M Noeth1, F H Van Zyl2, J Hellig3
1Zuid-Afrikaans Hospital, Pretoria; Department of Internal Medicine, University of Pretoria, South Africa.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
|December 11, 2025
概括
肥胖药物治疗,结合生活方式的改变,有助于体重管理,并预防2型糖尿病等并发症. 对于BMI为27-30+kg/m2的个体,有或没有并发症,建议使用经批准的药物.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一种复杂的慢性疾病,需要多方面的管理策略.
- 药物治疗与生活方式干预相结合,对于有效的肥胖管理起着至关重要的作用.
- 特定的患者群体可能会受益于有针对性的药物治疗方法.
研究的目的:
- 为在肥胖管理中使用药物治疗提供基于证据的建议.
- 概述药物治疗在减肥维护和重量恢复预防中的作用.
- 为肥胖和相关并发症患者指导药物治疗的选择.
主要方法:
- 对评估肥胖药物疗法的临床试验进行系统审查和元分析.
- 根据既定指南对证据的评分和建议的强度.
- 综合有关疗效,安全性和特定患者群体的数据.
主要成果:
- 对于BMI≥30 kg/m2或≥27 kg/m2并发症的个体,以及改变生活方式的患者,建议进行药物治疗.
- 特定的药物,如塞马格卢提德,利拉格卢提德,纳尔特雷克松/布罗和奥利斯塔特,得到不同程度的证据支持.
- 药物治疗有效地维持体重减轻,防止体重恢复,延迟2型糖尿病,改善阻塞性睡眠呼吸暂停和MASH等并发症.
- 建议在接受抗精神病药物的患者中使用甲福明和心理治疗来预防体重增加.
结论:
- 药物治疗是全面的肥胖管理的一个有价值的工具,当与生活方式的修改集成.
- 药物选择应根据患者的特征,并发病症和基于证据的建议进行个性化选择.
- 进一步的研究是有必要的,以探索新的药物治疗剂,并优化治疗策略,为不同的患者群体.
相关概念视频
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
01:21Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159
01:15Diabetes: Management and Pharmacotherapy
848
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
848
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:26Psychosis: Goals of Pharmacotherapy
441
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
441